Assessment of the acute bronchodilator test and the efficacy of the course of treatment with Glycopyrronium bromide in patients with pulmonary tuberculosis associated with chronic obstructive pulmonary disease

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Despite significant progress in the fight against tuberculosis, the number of new cases in the world remains relatively stable, and amounts are more than 10 million annually. Chronic obstructive pulmonary disease (COPD) negatively affects the quality of life in patients with pulmonary tuberculosis and reduces the effectiveness of chemotherapy. Correction of bronchial obstruction in pulmonary tuberculosis remains an actual problem.

Aim. To assess the acute bronchodilator test with glycopyrronium bromide, pulmonary function test parameters changing within 24 hours after inhalation, as well as the effect of a 2–3-month course of treatment with glycopyrronium bromide on the same parameters and the quality of life in patients with pulmonary tuberculosis associated with chronic obstructive pulmonary disease.

Material and methods. A prospective cohort study of 38 patients with active pulmonary tuberculosis associated with the chronic obstructive pulmonary disease treated with anti-tuberculosis chemotherapy was carried out. The pulmonary function test parameters were assessed before inhalation, 15, 30, 120 min, 23 h 45 min after a single inhalation of glycopyrronium bromide, as well as after 1, 2 and 3 months of treatment. Quality of life was assessed by using CAT (COPD Assessment Test), SF-36 (Short Form-36 Health Survey Questionnaire), SGRQ (St. Georges Respiratory questionnaire).

Results. A single inhalation of 50 μg glycopyrronium bromide led to a significant increase in forced expiratory volume in 1 second by +15.2%, +18.3%, +22.8% and +11.2% after 15, 30, 120 minutes and 23 h 45 min, respectively. The change in forced expiratory volume in 1 second after 1, 2 and 3 months of treatment was +13.1%, +9.3% and +11.7%, respectively. The overall CAT score after 3 months decreased by 7. The mental health index SF-36 increased by 9.2 points. A decrease in SGRQ parameters was revealed: symptoms — by 21.7 points, physical activity — by 14.8 points, impact — by 18.2 points.

Conclusion. Inhaled glycopyrronium bromide 50 μg once daily can be recommended for the treatment of patients with active pulmonary tuberculosis associated with chronic obstructive pulmonary disease.

Full Text

Restricted Access

About the authors

Marat F Yaushev

Kazan State Medical University

Author for correspondence.
Email: umukgmu@rambler.ru
ORCID iD: 0000-0001-6485-3166

MD, D.Sc. (Med.), Prof., Depart. of Phthisiopulmonology

Russian Federation, Kazan, Russia

Alexey P Alexeev

Kazan State Medical University

Email: guz.rkpd@tatar.ru
ORCID iD: 0000-0001-5334-2133

MD, D.Sc. (Med.), Prof., Depart. of Phthisiopulmonology

Russian Federation, Kazan, Russia

References

  1. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/9789240013131 (access date: 19.09.2021).
  2. Skvortsova ES, Borodulina EA, Osadchuk AM. Infiltrate pulmonary tuberculosis, gastric ulcer and hiv infection (comorbidity and multimorbidity). Tuberculosis and lung diseases. 2016; 94(12):62–66. (In Russ.) doi: 10.21292/2075-1230-2016-94-12-62-66.
  3. Bagisheva NV, Mordyk AV, Ivanova OG, Batishcheva TL. Tuberculosis and COPD: the problem of comorbidity. Meditsinskiy vestnik Severnogo Kavkaza. 2014;9(4):329–331. (In Russ.) doi: 10.14300/mnnc.2014.09092.
  4. Shmelev EI, Kuklina GM. Treatment of bronchial obstruction in patients with lung tuberculosis. Pulmonologiya. 2005;(5):39–45. (In Russ.)
  5. Khanin AL, Kravets CL. Chro­nic obstructive pulmonary disease and tuberculosis: the latest problem in real clinical practice (review). The Bulletin of contemporary clinical medicine. 2017;10(6):60–70. (In Russ.) doi: 10.20969/VSKM.2017.10(6).60-70.
  6. Chushkin MI, Mandrykin YuV, Yartsev SS, Belevsky AS, Meshcheryakova NN. Quality of life of patients recovered from pulmonary tuberculosis. Pulmonologiya. 2010;(2):88–90. (In Russ.) doi: 10.18093/0869-0189-2010-2-88-90.
  7. Bagisheva NV, Neganova YuA, Neganova NA, Mordyk AV, Ivanova OG, Batishcheva TL, Bezukladova AS. Chronic obstructive lung disease and tuberculosis as concurrent conditions. Tuberculosis and lung diseases. 2015;(6):21–22. (In Russ.)
  8. Bagisheva NV, Mordyk AV, Nesterova KI, Nebesnaya EYu, Aroyan AR, Batischeva TL. Inhaled glucocorticosteroids for complex therapy of patients with newly diagnosed pulmonary tuberculosis in combination with chronic obstructive pulmonary disease. Lechebnoe delo. 2020;(3):68–74. (In Russ.)
  9. Shmelev EI. Treatment of bronchial obstruction in patients with pulmonary tuberculosis. Mezhdunarodnyy meditsinskiy zhurnal. 2006;(4):54–58. (In Russ.)
  10. Shmelev EI, Kuklina GM. Modern principles of treatment of bronchial obstruction in patients with pulmonary tuberculosis. Problemy tuberkuleza. 2001;7:36–40. (In Russ.)
  11. Titova ON. Glycopyrronium bromide in the treatment of chronic obstructive pulmonary disease with stable flow. Russkiy me­ditsinskiy zhurnal. 2017;(11):808–814. (In Russ.)
  12. Miravitlles M, Beeh K-M, Altman P. Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clinical Investigation (London). 2014;4(12):1095–1111.
  13. Aisanov ZR, Avdeev SN, Arkhipov VV, Belevskiy AS, Leshchenko IV, Ovcharenko SI, Shmelev EI, Chuchalin AG. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary di­sease: a clinical decision-making algorithm. Pulmo­nologiya. 2017;27(1):13–20. (In Russ.) doi: 10.18093/0869-0189-2017-27-1-13-20.
  14. Amir­djanova VN, Goryachev DV, Korshunov NI, Rebrov AP, Sorotskaya VN. SF-36 questionnaire population quality of life indices objective. Rheumatology science and practice. 2008;(1):36–48. (In Russ.)

Supplementary files

There are no supplementary files to display.


© 2022 Eco-Vector





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies